SCHOLAR ROCK HOLDING CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.3 USD | -2.24% |
|
-12.41% | -56.06% |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to Scholar Rock's ca...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Company to develop a proprietary platform for the development of monoclonal antibodies that locally and selectively target the precursor. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as the first muscle-targeted therapy for the treatment of spinal muscular atrophy (SMA). Its other product candidate, SRK-181, a selective inhibitor of the activation of latent TGFb, is being developed for the treatment of cancers.
Calendar
2024-06-27
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.49
USD
Average target price
26.5
USD
Spread / Average Target
+212.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.06% | 677M | |
| +14.40% | 121B | |
| +17.05% | 112B | |
| +3.81% | 22.57B | |
| -18.35% | 20.82B | |
| -15.05% | 16.3B | |
| -16.77% | 16.19B | |
| -42.36% | 16.17B | |
| +0.99% | 13.17B | |
| +23.40% | 11.11B |
- Stock Market
- Equities
- SRRK Stock
- News Scholar Rock Holding Corporation
- Transcript : Scholar Rock Holding Corporation - Special Call
